Phase 1 Data on MM-398 will be Presented at the ASCO 2012 Gastrointestinal Cancers Symposium
CAMBRIDGE, Mass., Jan. 12, 2012 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. announced today that Phase 1 results on MM-398, one of its five targeted therapeutic oncology candidates in clinical development, will be presented at the ASCO 2012 Gastrointestinal Cancers Symposium being held January 19 – 21, 2012, in San Francisco, CA.
MM-398 is a novel, stable nanotherapeutic encapsulation of irinotecan. The U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for use in the treatment of pancreatic cancer. PharmaEngine, Inc. has rights to develop and commercialize MM-398 in Taiwan under the designation PEP02.
Title: Phase I Study of Biweekly Liposome Irinotecan (PEP02, MM- 398) in Metastatic Colorectal Cancer After First-line Oxaliplatin-based Chemotherapy Poster Session: General Poster Session C: Cancers of the Colon and Rectum Number: 613 Date/Time: Saturday, January 21st, 2012/ 7:00 AM -8:00 AM; 12:30 PM -2:30 PM Location: Level 1, West Hall ----------------------------
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.
Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, email@example.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, firstname.lastname@example.org
SOURCE Merrimack Pharmaceuticals, Inc.